Biosimilars Forum Encouraged by Trump Administration’s Support for Biosimilars
WASHINGTON, D.C., May 11, 2018 – Juliana M. Reed, President of the Biosimilars Forum, a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care, released the following statement in response to President Trump’s remarks today about drug pricing, and the release of the White House plan to lower drug prices.
“The Biosimilars Forum is encouraged by President Trump’s and his administration’s interest in increasing patient access to more affordable treatment options, including supporting the development of a competitive biosimilars market, which has the potential to drive down health care costs over time,” said Juliana M. Reed, President of the Biosimilars Forum. “We were pleased that the plan specifically notes the Food and Drug Administration’s recently launched education initiative, demonstrating that it prioritizes raising awareness about the potential of biosimilars to lower costs while providing the same safety and effectiveness as their reference biologic drugs.
“Ultimately, the emergence of a more vibrant biosimilars market in the United States that will provide access to biosimilars for patients, physicians and the entire health care system will allow this country to realize the benefits such treatments can provide.”
About the Biosimilars Forum
The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.
Samantha Kupferman, Marathon Strategies
Office: 212-256-9843; Cell: 202-215-9260